Allenex AB (LTS:0O9J) Total Current Liabilities : £3.49 Mil (As of Mar. 2016)

Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.